Therapeutic consultation centres are helpful in developing countries
Editor-The increasing global gap between rich and poor countries leads to inequalities in access to drugs and to the knowledge and skills needed for their rational use. It also leads to qualitatively different information needs.
Therapeutic information on the management of HIV infection and AIDS flows at two separate levels: although some doctors debate about the potential benefits of new viral transmembrane protein blockers, others are wondering how to manage a patient with pneumocystis pneumonia because of insufficient financial resources to purchase co-trimoxazole. These people could benefit from local therapeutic consultation centres, especially in countries where the prevalence of HIV infection and AIDS is high and access to appropriate treatment (not only to triple antiretroviral therapy) is unaffordable.
Therapeutic consultation centres are one of the most relevant service activities of clinical pharmacology, 1 supplying problem oriented information for inquiries on individual patients or on factual knowledge. [2] [3] [4] [5] In prevention and control programmes for HIV infection and AIDS such a centre specialising in managing these conditions can give quick, expert, and locally focused answers to common problems. For example, it can give advice on prescription and dose adjustments needed in special situations such as pregnancy, paediatrics, and anaemia; best available management for opportunistic infections; confounding side effects (that is, side effects not identified as such); failure to identify drug interactions; best alternatives when there is no drug (or when drugs are scarce or unaffordable); and advice when appropriate treatment proves ineffective.
A therapeutic consultation centre could: x Develop local guidelines x Develop the content of and tools for undergraduate teaching and continuous education x Participate in campaigns on general health and sexual education x Give advice to policy makers, drug regulatory authorities, and healthcare providers on drug selection x Monitor prescription and use of treatment to identify inappropriate practices, with particular emphasis on outcome research x Contribute to the management of international drug donations x Design and conduct studies on specific issues (for example, transferability of the results of clinical trials performed in other settings, identifying subgroups for which evidence is lacking, cultural perceptions, interactions with non-conventional treatments, adherence).
Such a centre would need political will and support from local authorities, training, continuous external support, and funding. It should include people trained in both infectious diseases (particularly HIV infection and AIDS) and clinical pharmacology, an internet connection, and access to essential drug information sources and medical publications. One such centre will be set up in the Dominican Republic with the support of the World Bank as part of the framework of the multicountry HIV/AIDS prevention and control programme for the Caribbean region. Now, 20 years since the first appearance of the virus, is a good time to review the advances to date and identify promising avenues for future research.
To estimate the amount of money spent on research on HIV and, within that, the amount spent on animal studies is difficult. Assessments of the efficacy of animal studies in HIV research are, however, easier to come by.
Thomas Insel, former director of the Yerkes Regional Primate Center in Georgia, said: "[An animal model] that takes 12-14 years to develop doesn't sound to me to be ideal . . . I can't tell you what it is that those studies [with chimpanzees] have given us that has really made a difference in the way we approach people with this disease."
2 Animal models of HIV have been notoriously inaccurate for two reasons.
Firstly, the immune response is intensely complicated and there are many disparities between the human immune response and those of other animals. Secondly, viruses are usually species specific.
In terms of treatment, the efficacy of zidovudine-originally an anticancer drugwas shown in 1985 from the results of in vitro studies rather than animal research. Similarly, combination antiretroviral therapy was developed using in vitro methods, rational drug design, and clinical research.
In vitro research has also enabled other advances in understanding and potentially treating HIV. These include elucidating the structure of the virus (and recently the rare b12 antibody), finding that an HIV-1 entry inhibitor could prevent HIV from fusing with the cell membrane, 3 and discovering that certain strains of HIV do not use the normal 2-receptor binding process but bind directly to T helper cells via the CD8 receptor. 4 Epidemiological studies determined the routes of HIV transmission. Gene variants that influence HIV progression were identified using longitudinal epidemiological cohort studies, high throughput genotyping and polymorphism discovery methods, and computational algorithms to detect gene associations in cohorts with the disease.
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The fact that 20 years on there is still no cure or vaccine for HIV is surely partly because too much money, time, and effort have been invested in animal research which has produced little, if nothing, in return. To make any impact on this global pandemic during the next 20 years, funding needs to be concentrated on research methods that have come up with the goods.
